Elecoglipron
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Pressure score
47
Momentum score
24
Why This Matters
Roche is a direct competitive threat because it has a Phase III program in Endocrinology · Obesity (Elecoglipron) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Roche's Elecoglipron directly references the same indication focus (Endocrinology · Obesity) as this signal.
Source: Roche
View source documentRelated Signal
AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Lilly
1 competitive finding
Top program: Elecoglipron
- Pressure
- 74
- Momentum
- 55
- Threat
- commercial competitor
- Stage
- Approved
74LillyHighElecoglipron·Approved
Roche
2 competitive findings
Top program: Elecoglipron
- Pressure
- 47
- Momentum
- 24
- Threat
- direct competitor
- Stage
- Phase III
47RocheMediumElecoglipron·Phase III